LaQuisa Hill

786 total citations
26 papers, 368 citations indexed

About

LaQuisa Hill is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, LaQuisa Hill has authored 26 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 8 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in LaQuisa Hill's work include CAR-T cell therapy research (19 papers), Viral Infectious Diseases and Gene Expression in Insects (6 papers) and Silicon Carbide Semiconductor Technologies (5 papers). LaQuisa Hill is often cited by papers focused on CAR-T cell therapy research (19 papers), Viral Infectious Diseases and Gene Expression in Insects (6 papers) and Silicon Carbide Semiconductor Technologies (5 papers). LaQuisa Hill collaborates with scholars based in United States, India and Canada. LaQuisa Hill's co-authors include Helen E. Heslop, Premal Lulla, Malcolm K. Brenner, Katayoun Rezvani, Partow Kebriaei, Elizabeth J. Shpall, Rohtesh S. Mehta, Amin M. Alousi, Carlos A. Ramos and Maksim Mamonkin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Current Opinion in Immunology.

In The Last Decade

LaQuisa Hill

25 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
LaQuisa Hill United States 11 265 132 91 83 72 26 368
Alberto Mussetti Spain 13 251 0.9× 97 0.7× 44 0.5× 196 2.4× 96 1.3× 51 435
Carrie Yuen United States 7 284 1.1× 123 0.9× 102 1.1× 77 0.9× 163 2.3× 19 470
Chunrong Tong China 11 337 1.3× 113 0.9× 86 0.9× 104 1.3× 108 1.5× 50 450
Alessandro Crotta United States 7 273 1.0× 55 0.4× 43 0.5× 99 1.2× 48 0.7× 26 369
Christine Dehner United States 11 402 1.5× 112 0.8× 74 0.8× 153 1.8× 88 1.2× 19 520
Eugenio Galli Italy 9 176 0.7× 49 0.4× 50 0.5× 46 0.6× 37 0.5× 43 280
Liora M. Schultz United States 10 347 1.3× 202 1.5× 77 0.8× 50 0.6× 132 1.8× 41 455
Victor A. Chow United States 8 214 0.8× 50 0.4× 40 0.4× 51 0.6× 80 1.1× 29 359
Jiazhen Cui China 11 312 1.2× 118 0.9× 76 0.8× 74 0.9× 139 1.9× 39 423

Countries citing papers authored by LaQuisa Hill

Since Specialization
Citations

This map shows the geographic impact of LaQuisa Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by LaQuisa Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites LaQuisa Hill more than expected).

Fields of papers citing papers by LaQuisa Hill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by LaQuisa Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by LaQuisa Hill. The network helps show where LaQuisa Hill may publish in the future.

Co-authorship network of co-authors of LaQuisa Hill

This figure shows the co-authorship network connecting the top 25 collaborators of LaQuisa Hill. A scholar is included among the top collaborators of LaQuisa Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with LaQuisa Hill. LaQuisa Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shafer, Paul, Maksim Mamonkin, LaQuisa Hill, et al.. (2024). Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 143(17). 1726–1737. 9 indexed citations
2.
Alousi, Amin M., Jin S. Im, LaQuisa Hill, et al.. (2024). Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplantation. 59(11). 1594–1600. 1 indexed citations
3.
Muhsen, Ibrahim N., Tao Wang, Meng-Fen Wu, et al.. (2024). Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy. 30(12). 1193.e1–1193.e8. 2 indexed citations
4.
Wang, Tao, Meng‐Fen Wu, Thomas Pfeiffer, et al.. (2024). Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 26(9). 1026–1032.
5.
Ma, Royce, Mae Woods, Dayenne G. van Leeuwen, et al.. (2024). Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Reports Medicine. 5(7). 101628–101628. 5 indexed citations
6.
Ramos, Carlos A., Amy N. Courtney, Premal Lulla, et al.. (2024). Off-the-Shelf CD19-Specific CAR-NKT Cells in Patients with Relapsed or Refractory B-Cell Malignancies. Transplantation and Cellular Therapy. 30(2). S41–S42. 15 indexed citations
7.
Muhsen, Ibrahim N., LaQuisa Hill, & Carlos A. Ramos. (2023). Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematology/Oncology Clinics of North America. 37(6). 1107–1124. 3 indexed citations
8.
Hill, LaQuisa, Rayne H. Rouce, Meng-Fen Wu, et al.. (2023). Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 143(13). 1231–1241. 30 indexed citations
9.
Furqan, Fateeha, Kwang Woo Ahn, Yue Chen, et al.. (2022). Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. British Journal of Haematology. 200(1). 54–63. 1 indexed citations
10.
Friend, Brian D., Ibrahim N. Muhsen, Shreeya Patel, et al.. (2022). Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation. 57(4). 579–585. 1 indexed citations
11.
Vasileiou, Spyridoula, LaQuisa Hill, Manik Kuvalekar, et al.. (2022). Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 108(7). 1840–1850. 16 indexed citations
12.
Watanabe, Norihiro, Feiyan Mo, Rong Zheng, et al.. (2022). Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Molecular Therapy. 31(1). 24–34. 45 indexed citations
13.
Vasileiou, Spyridoula, Manik Kuvalekar, Ayumi Watanabe, et al.. (2021). Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19. Transplantation and Cellular Therapy. 27(3). S348–S349. 3 indexed citations
14.
Rouce, Rayne H., LaQuisa Hill, Tyler S. Smith, et al.. (2021). Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma. Blood. 138(Supplement 1). 654–654. 14 indexed citations
15.
Heslop, Helen E., et al.. (2021). Beyond CD19 CAR-T cells in lymphoma. Current Opinion in Immunology. 74. 46–52. 8 indexed citations
16.
Streck, Brennan Parmelee, George Carrum, LaQuisa Hill, et al.. (2021). Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplantation and Cellular Therapy. 27(9). 785.e1–785.e6. 3 indexed citations
17.
Vasileiou, Spyridoula, Manik Kuvalekar, Ayumi Watanabe, et al.. (2021). 37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains. Open Forum Infectious Diseases. 8(Supplement_1). S27–S27. 2 indexed citations
18.
Hadidi, Samer Al, Deepa Dongarwar, Hamisu M. Salihu, et al.. (2021). Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leukemia & lymphoma. 62(13). 3256–3263. 20 indexed citations
19.
Hill, LaQuisa, Rayne H. Rouce, Tyler S. Smith, et al.. (2019). Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies. Blood. 134(Supplement_1). 199–199. 51 indexed citations
20.
Hill, LaQuisa, Premal Lulla, & Helen E. Heslop. (2019). CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm. PubMed. 2(3). 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alberto Mussetti Breakdown of academic impact, for papers by Carrie Yuen Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Christine Dehner Breakdown of academic impact, for papers by Eugenio Galli Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Victor A. Chow Breakdown of academic impact, for papers by Jiazhen Cui
Rankless by CCL
2026